Nisa Investment Advisors LLC Has $8.74 Million Stake in Regeneron Pharmaceuticals Inc (REGN)

Nisa Investment Advisors LLC lifted its stake in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 16.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,642 shares of the biopharmaceutical company’s stock after purchasing an additional 3,098 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $8,744,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the company. Wrapmanager Inc. raised its stake in shares of Regeneron Pharmaceuticals by 9.9% during the second quarter. Wrapmanager Inc. now owns 1,440 shares of the biopharmaceutical company’s stock worth $497,000 after purchasing an additional 130 shares during the last quarter. Raymond James Financial Services Advisors Inc. raised its stake in shares of Regeneron Pharmaceuticals by 4.7% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 3,144 shares of the biopharmaceutical company’s stock worth $1,085,000 after purchasing an additional 141 shares during the last quarter. Traynor Capital Management Inc. raised its stake in shares of Regeneron Pharmaceuticals by 9.8% during the second quarter. Traynor Capital Management Inc. now owns 1,631 shares of the biopharmaceutical company’s stock worth $572,000 after purchasing an additional 145 shares during the last quarter. Atria Investments LLC raised its position in Regeneron Pharmaceuticals by 10.9% in the second quarter. Atria Investments LLC now owns 1,497 shares of the biopharmaceutical company’s stock worth $516,000 after acquiring an additional 147 shares in the last quarter. Finally, MUFG Securities EMEA plc raised its position in Regeneron Pharmaceuticals by 1.7% in the second quarter. MUFG Securities EMEA plc now owns 9,031 shares of the biopharmaceutical company’s stock worth $3,116,000 after acquiring an additional 152 shares in the last quarter. Institutional investors and hedge funds own 66.28% of the company’s stock.

Regeneron Pharmaceuticals stock opened at $389.83 on Friday. The company has a current ratio of 3.62, a quick ratio of 2.92 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $43.12 billion, a price-to-earnings ratio of 29.07, a PEG ratio of 1.33 and a beta of 1.12. Regeneron Pharmaceuticals Inc has a fifty-two week low of $281.89 and a fifty-two week high of $437.90.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, August 2nd. The biopharmaceutical company reported $5.45 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $4.60 by $0.85. The company had revenue of $1.61 billion for the quarter, compared to analyst estimates of $1.56 billion. Regeneron Pharmaceuticals had a return on equity of 29.30% and a net margin of 25.65%. Regeneron Pharmaceuticals’s revenue was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $4.17 earnings per share. Equities analysts predict that Regeneron Pharmaceuticals Inc will post 19.4 EPS for the current year.

Several research firms have issued reports on REGN. BidaskClub upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday. Morgan Stanley increased their price objective on Regeneron Pharmaceuticals from $409.00 to $412.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 11th. Canaccord Genuity increased their price objective on Regeneron Pharmaceuticals from $390.00 to $410.00 and gave the stock a “hold” rating in a research report on Thursday, October 11th. JPMorgan Chase & Co. reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Tuesday, October 2nd. Finally, Leerink Swann increased their price objective on Regeneron Pharmaceuticals from $506.00 to $512.00 and gave the stock an “outperform” rating in a research report on Monday, October 1st. Two analysts have rated the stock with a sell rating, sixteen have given a hold rating and eight have given a buy rating to the company’s stock. Regeneron Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $412.19.

In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 2,000 shares of the company’s stock in a transaction on Thursday, September 27th. The stock was sold at an average price of $392.26, for a total value of $784,520.00. Following the sale, the director now owns 2,000 shares of the company’s stock, valued at $784,520. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michael S. Brown sold 1,500 shares of the company’s stock in a transaction on Wednesday, August 22nd. The shares were sold at an average price of $380.49, for a total value of $570,735.00. Following the completion of the sale, the director now directly owns 1,500 shares in the company, valued at approximately $570,735. The disclosure for this sale can be found here. Insiders sold 112,052 shares of company stock worth $45,411,762 in the last three months. 12.42% of the stock is owned by corporate insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Recommended Story: Price to Earnings Ratio (PE)

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply